Literature DB >> 20357801

Liraglutide.

Daniel J Drucker1, Argyris Dritselis, Peter Kirkpatrick.   

Abstract

In January 2010, liraglutide (Victoza; Novo Nordisk)--an injectable glucagon-like peptide 1 receptor agonist--was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20357801     DOI： 10.1038/nrd3148

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  14 in total

Review 1.  Incretin-based therapies for type 2 diabetes mellitus.

Authors:  Julie A Lovshin; Daniel J Drucker
Journal:  Nat Rev Endocrinol       Date:  2009-05       Impact factor: 43.330

2.  Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

Authors:  Lotte Bjerre Knudsen; Lars Wichmann Madsen; Søren Andersen; Kasper Almholt; Anne S de Boer; Daniel J Drucker; Carsten Gotfredsen; Frederikke Lihme Egerod; Anne Charlotte Hegelund; Helene Jacobsen; Søren Dyring Jacobsen; Alan C Moses; Anne-Marie Mølck; Henriette S Nielsen; Jette Nowak; Helene Solberg; Tu D L Thi; Milan Zdravkovic; Ulrik Moerch
Journal:  Endocrinology       Date:  2010-03-04       Impact factor: 4.736

3.  Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies.

Authors:  Kiwon Ban; Sonya Hui; Daniel J Drucker; Mansoor Husain
Journal:  J Am Soc Hypertens       Date:  2009-06-03

4.  Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Authors:  Alan Garber; Robert Henry; Robert Ratner; Pedro A Garcia-Hernandez; Hiromi Rodriguez-Pattzi; Israel Olvera-Alvarez; Paula M Hale; Milan Zdravkovic; Bruce Bode
Journal:  Lancet       Date:  2008-09-24       Impact factor: 79.321

5.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Authors:  John B Buse; Julio Rosenstock; Giorgio Sesti; Wolfgang E Schmidt; Eduard Montanya; Jason H Brett; Marcin Zychma; Lawrence Blonde
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

6.  Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

Authors:  Daniel J Drucker; John B Buse; Kristin Taylor; David M Kendall; Michael Trautmann; Dongliang Zhuang; Lisa Porter
Journal:  Lancet       Date:  2008-09-07       Impact factor: 79.321

7.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

Authors:  D Russell-Jones; A Vaag; O Schmitz; B K Sethi; N Lalic; S Antic; M Zdravkovic; G M Ravn; R Simó
Journal:  Diabetologia       Date:  2009-08-14       Impact factor: 10.122

8.  Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.

Authors:  Daniel J Drucker; Steven I Sherman; Fred S Gorelick; Richard M Bergenstal; Robert S Sherwin; John B Buse
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

9.  Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Authors:  Michael Nauck; Anders Frid; Kjeld Hermansen; Nalini S Shah; Tsvetalina Tankova; Ismail H Mitha; Milan Zdravkovic; Maria Düring; David R Matthews
Journal:  Diabetes Care       Date:  2008-10-17       Impact factor: 17.152

10.  Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert Sherwin; Bernard Zinman
Journal:  Diabetes Care       Date:  2008-10-22       Impact factor: 17.152
View more
  38 in total

1.  Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function.

Authors:  Cassandra Koole; Denise Wootten; John Simms; Emilia E Savage; Laurence J Miller; Arthur Christopoulos; Patrick M Sexton
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

2.  Biopharmaceutical benchmarks 2010.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2010-09       Impact factor: 54.908

Review 3.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

4.  Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β.

Authors:  Liqin Qi; Zhou Chen; Yanping Wang; Xiaoying Liu; Xiaohong Liu; Linfang Ke; Zhongjie Zheng; Xiaowei Lin; Yu Zhou; Lijuan Wu; Libin Liu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

5.  Regulation of adipocyte formation by GLP-1/GLP-1R signaling.

Authors:  Tenagne Delessa Challa; Nigel Beaton; Myrtha Arnold; Gottfried Rudofsky; Wolfgang Langhans; Christian Wolfrum
Journal:  J Biol Chem       Date:  2011-12-29       Impact factor: 5.157

6.  Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection.

Authors:  Kellie M Hyde; Ginger D Blonde; Carel W le Roux; Alan C Spector
Journal:  Physiol Behav       Date:  2017-03-30

7.  GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.

Authors:  Minsuk Kim; Mathew J Platt; Tadao Shibasaki; Susan E Quaggin; Peter H Backx; Susumu Seino; Jeremy A Simpson; Daniel J Drucker
Journal:  Nat Med       Date:  2013-03-31       Impact factor: 53.440

8.  Liraglutide Promotes Cortical Neurite Outgrowth via the MEK-ERK Pathway.

Authors:  Meng Li; Shilun Li; Yukun Li
Journal:  Cell Mol Neurobiol       Date:  2015-04-11       Impact factor: 5.046

9.  High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.

Authors:  Joram D Mul; Denovan P Begg; Jason G Barrera; Bailing Li; Emily K Matter; David A D'Alessio; Stephen C Woods; Randy J Seeley; Darleen A Sandoval
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-24       Impact factor: 3.619

10.  Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.

Authors:  Jing Han; Lidan Sun; Xun Huang; Zheng Li; Chenyu Zhang; Hai Qian; Wenlong Huang
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.